当前位置: X-MOL 学术Int. J. Gen. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Colchicine in Recently Hospitalized Patients with COVID-19: A Randomized Controlled Trial (COL-COVID)
International Journal of General Medicine ( IF 2.1 ) Pub Date : 2021-09-11 , DOI: 10.2147/ijgm.s329810
Domingo A Pascual-Figal 1, 2, 3 , Aychel E Roura-Piloto 4 , Encarnación Moral-Escudero 4 , Enrique Bernal 5 , Helena Albendín-Iglesias 4 , M Teresa Pérez-Martínez 1 , Jose Antonio Noguera-Velasco 6 , Iria Cebreiros-López 6 , Álvaro Hernández-Vicente 1 , David Vázquez-Andrés 1 , Carmen Sánchez-Pérez 2 , Amjad Khan 7 , Fátima Sánchez-Cabo 3 , Elisa García-Vázquez 4 ,
Affiliation  

Background: Colchicine has been proposed as a potential therapy in coronavirus disease 2019 (COVID-19) due to their anti-inflammatory actions.
Methods: The COL-COVID study was a prospective, randomized, controlled and open-label clinical trial that compared colchicine added to standard treatment vs standard treatment in hospitalized COVID-19 patients that do not need mechanical ventilatory support. Colchicine was initiated within the first 48 hours of admission at a 1.5 mg loading dose, followed by 0.5 mg b.i.d. for one week and 0.5 mg per day for 28 days. The study endpoints were clinical status (7-points WHO ordinal scale) and inflammatory biomarkers (IL-6 and CRP).
Results: A total of 103 patients (51± 12 years, 52% male) were randomly allocated to colchicine arm (n=52) and control arm (n=51). At day 28, all patients in the colchicine group were alive and discharged, whereas in the control group, two patients died in-hospital and one patient remained hospitalized. Clinical improvement in terms of changes on WHO scale at day 14 and 28 and time to 1-point clinical improvement did not differ between the two groups. Clinical deterioration (increase of at least 1-point in WHO scale) was observed in a higher proportion of cases in colchicine group (13.8%) vs control group (5.8%) (p=0.303); after adjustment by baseline risk factors and concomitant therapies, colchicine therapy was associated with a lower risk of clinical deterioration (p=0.030). Inflammatory biomarkers CRP and IL-6 concentrations course did not differ between the two arms.
Conclusion: In hospitalized COVID-19 patients, colchicine treatment neither improved the clinical status, nor the inflammatory response, over the standard treatment. Nevertheless, a preventive effect for further clinical deterioration might be possible.
Trial Registration: NCT04350320.



中文翻译:


秋水仙碱在最近住院的 COVID-19 患者中的作用:一项随机对照试验 (COL-COVID)



背景:秋水仙碱因其抗炎作用而被提议作为 2019 年冠状病毒病 (COVID-19) 的潜在疗法。

方法: COL-COVID 研究是一项前瞻性、随机、对照和开放标签的临床试验,比较了标准治疗中添加秋水仙碱与不需要机械通气支持的住院 COVID-19 患者的标准治疗。秋水仙碱在入院后 48 小时内开始服用 1.5 mg 负荷剂量,随后一周 0.5 mg bid,每天 0.5 mg,持续 28 天。研究终点是临床状态(7 点 WHO 顺序量表)和炎症生物标志物(IL-6 和 CRP)。

结果:共有 103 名患者(51±12 岁,52% 男性)被随机分配到秋水仙碱组 (n=52) 和对照组 (n=51)。第28天,秋水仙碱组的所有患者均存活并出院,而对照组有两名患者在院内死亡,一名患者仍在住院。就第 14 天和第 28 天的 WHO 量表变化以及达到 1 点临床改善的时间而言,两组之间的临床改善没有差异。与对照组 (5.8%) 相比,秋水仙碱组 (13.8%) 的病例比例较高 (p=0.303);观察到临床恶化(世界卫生组织评分至少增加 1 分);经过基线危险因素和伴随治疗调整后,秋水仙碱治疗与较低的临床恶化风险相关(p=0.030)。炎症生物标志物 CRP 和 IL-6 浓度过程在两组之间没有差异。

结论:在住院的 COVID-19 患者中,与标准治疗相比,秋水仙碱治疗既没有改善临床状态,也没有改善炎症反应。尽管如此,对临床进一步恶化的预防作用还是有可能的。

试用注册: NCT04350320。

更新日期:2021-09-12
down
wechat
bug